Clinical Trial Update: Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial investigating addition of X4P-001 to nivolumab in clear cell renal cell carcinoma; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• X4P-001
• nivolumab (nivolumab)

Snippet

Sponsor: X4 Pharmaceuticals | Conditions: Clear Cell Renal Cell Carcinoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-12-29